Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genotype-directed fluoropyrimidine dosing for DPYD variant carriers
NL-OMON45080Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Apr 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of capecitabine and fluorouracil in breast cancer, colorectal cancer (CRC) and gastric cancer (GC) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Incidence of severe treatment-related toxicity. Started Apr 2015; status: recruiting.
02
Drugs
capecitabinefluorouracil
03
Conditions
breast cancercolorectal cancer (CRC)gastric cancer (GC)
Beyond the preview
Go deeper on NL-OMON45080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45080.